Search the Newsreel

EPSN | Epsilon Energy Ltd. Financials - Revenue Breakdown

Epsilon Energy (EPSN) Stock Sinks Despite Sharp Profit Rebound

Epsilon Energy (EPSN) saw its stock drop 10% despite reporting a sharp rebound in profit for Q2 2026, with revenue at US$18.3 million and net income at US$7.1 million. The company, which had reported losses over the last year, showed strong margin improvement as …

Silo Pharma (SILO) trims cash burn, mitigates going-concern risk in Q2 2026

Silo Pharma, Inc. (SILO) reported a net loss of $2.48 million for the six months ended June 30, 2026, driven by operational costs and R&D investments, despite generating $18,026 in license fee revenue. The company maintains a strong liquidity position with $3.28 million in …

Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Epsilon Energy issues Q3 and FY2026 production and $42–47M capital guidance

Epsilon Energy (EPSN) has provided its production guidance for Q3 and full-year 2026, alongside outlining a capital program of $42.0–47.0 million for FY2026. The company expects Q3 production between 3,270–3,510 MMcfe and FY2026 production of 13,740–14,280 MMcfe. This capital program includes significant investments in …

Form 8K Epsilon Energy Ltd For: 13 August By Investing.com

This article reports on an SEC Form 8K filing by Epsilon Energy Ltd on August 13th, as covered by Investing.com. The brief announcement provides no specific details about the content of the 8K filing, only noting its publication date. The article also includes various …

Silo Pharma (SILO) investor group discloses 9.99% warrant-based ownership cap

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% beneficial ownership in Silo Pharma, Inc. (SILO) as of June 30, 2026. This ownership, totaling 125,261 shares, is derived entirely from the exercise of warrants and is capped …

Epsilon Energy corrects Q2 adjusted net income to $0.03 loss per share

Epsilon Energy corrected its Q2 FY26 adjusted net income to a loss of $0.03 per share, revising an earlier report of $0.05 earnings, due to reclassifying asset sale proceeds. Despite a 57% revenue increase to $18.3 million, adjusted EBITDA fell 21% to $5.8 million, …

Epsilon Energy (NASDAQ:EPSN) Releases Earnings Results

Epsilon Energy corrects Q2 EPS to $0.03 loss, issues H2 guidance

Epsilon Energy Q2 EPS rises 229% to $0.23; revenue up 57%

Epsilon Energy Ltd. Reports Second Quarter 2026 Results and Provides Full-Year Guidance

Epsilon Energy GAAP EPS of $0.23, revenue of $18.26M

* Epsilon Energy press release [https://seekingalpha.com/pr/20617491-epsilon-announces-second-quarter-2026-results-and-2026-production-and-capital-guidance] (EPSN [https://seekingalpha.com/symbol/EPSN]): Q2 GAAP EPS of $0.23. * Revenue of $18.26M (+57.1% Y/Y). MORE ON EPSILON ENERGY * Epsilon Energy: Just In Time Expansion Into Oil [https://seekingalpha.com/article/4910384-epsilon-energy-just-in-time-expansion-into-oil] * Historical earnings data for Epsilon Energy [https://seekingalpha.com/symbol/EPSN/earnings] * Dividend scorecard …

Epsilon Announces Second Quarter 2026 Results and 2026 Production and Capital Guidance

Epsilon Energy Ltd. HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. ("Epsilon" or the "Company") (NASDAQ: EPSN) today reported second quarter 2026 financial and operating results. Q2 2026 Highlights: Epsilon - Q2 2026 Q2 2026 Q1 2026 Q2 2025 QoQ% YoY% NRI …

Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com

Silo Pharma (NASDAQ:SILO) has been granted a European patent for its SPC-15 treatment candidate, an intranasal therapy aimed at preventing post-traumatic stress disorder and stress-induced affective disorders. The patent covers methods for preventing stress-induced fear and depressive-like behavior by administering serotonin 4 receptor agonists. …

Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy

Silo Pharma has secured a European patent for its lead candidate, SPC-15, an intranasal treatment designed to prevent PTSD and other stress-induced psychiatric disorders. This patent strengthens Silo's intellectual property and allows for the commercialization of SPC-15 in Europe, complementing existing global protections. The …

A nasal PTSD treatment is patented for use before extreme stress

Silo Pharma (Nasdaq: SILO) has been granted a European patent (EP3952852) for SPC-15, its novel intranasal PTSD therapy. This patent covers methods of using specific serotonin 4 (5-HT4) receptor agonists to prevent stress-induced fear and depressive-like behavior when administered before extreme stress exposure, expanding …

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

Silo Pharma has been granted a European patent for its novel PTSD therapy, SPC-15, which uses an intranasal, nose-to-brain treatment targeting post-traumatic stress disorder and stress-induced affective disorders. The patent covers methods of preventing stress-induced fear and depressive-like behavior by administering serotonin 4 receptor …

Silo Pharma Inc (SILO) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast overview for Silo Pharma Inc (SILO), indicating that no earnings forecast score is currently available for the company, contrasting with the Pharmaceuticals industry's average score of 7.86. It also notes the absence of analyst ratings and target prices, …

Silo Pharma, Inc. SEC Filing (Aug 7, 2026)

This article reports on an SEC filing by Silo Pharma, Inc. (NASDAQ: SILO) that became effective on August 6, 2026, for a Form S-3 shelf registration. The filing had a neutral impact and sentiment according to AI-generated analysis. The article also provides recent news …

Sei Investments Co. Acquires 242,196 Shares of Epsilon Energy Ltd. $EPSN

Sei Investments Co. significantly increased its stake in Epsilon Energy Ltd. (NASDAQ:EPSN) by acquiring 242,196 additional shares in the first quarter, bringing its total ownership to 484,665 shares. This acquisition makes Sei Investments Co. one of several institutional investors actively trading Epsilon Energy shares, …

Epsilon Energy Ltd (EPSN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Epsilon Energy Ltd (EPSN), noting that no earnings forecast score is currently available, contrasting with the Oil & Gas industry average. It highlights a consensus price target of $8.40 from zero analysts, indicating a potential 46.60% upside. …

Epsilon Energy (EPSN.US) will release its earnings report after market close on August 12.

Epsilon Energy (EPSN.US) is scheduled to release its earnings report after the market closes on August 12. This announcement provides investors with the date to anticipate the company's financial results.

Silo Pharma (NASDAQ: SILO) files resale registration for 1.9M common shares

Silo Pharma Inc. (NASDAQ: SILO) has filed a resale registration for up to 1,906,392 common shares held by selling shareholders. The company will not receive proceeds from these resales, but may receive approximately $8.07 million if associated warrants are exercised for cash. Silo Pharma …

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon

Silo Pharma's subsidiary, QwikAgents, has partnered with Caylent, an AWS Premier Tier Services Partner, to build a new AWS-native platform. This collaboration aims to enhance the scalability, performance, and security of QwikAgents' AI platform for enterprise deployment and future innovation. The initiative is also …

(EPSN) Price Dynamics and Execution-Aware Positioning

This article analyzes Epsilon Energy Ltd. (NASDAQ: EPSN) using AI models, identifying a neutral sentiment in the near and mid-term with a long-term positive bias. It highlights an exceptional risk-reward short setup and outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with …

SILO|Silo Pharma Inc|Price:4.210|Chg%:+0.020

This article provides a detailed financial overview of Silo Pharma Inc (SILO), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. It includes live stock price, chart data, key financial figures, technical analysis, and ownership details. The company focuses on addressing underserved conditions like stress-induced …

Silo Pharma, Inc. Revenue Breakdown – NASDAQ:SILO

Silo Pharma, Inc. (NASDAQ: SILO) generated its entire reported revenue from the United States, totaling $72.10K USD in both the last year and the year prior. This data highlights the company's sole identified revenue segment and geographical market.

Epsilon Energy updates financial calendar with second-quarter earnings release and conference call

Epsilon Energy has announced its financial calendar, scheduling the release of its second-quarter 2026 earnings for August 12, 2026. A conference call to discuss these results will follow on August 13, 2026, at 10:00 a.m. CT, with a webcast available for attendees. The information …

Epsilon Energy Q2 Results: Earnings Release Scheduled for August 12

Epsilon Energy Ltd. announced that its second quarter 2026 earnings release will be issued after market close on August 12, 2026. A conference call to discuss these financial and operating results is scheduled for August 13, 2026, at 10:00 a.m. Central Time. The company, …

North American gas and oil company sets Aug. 13 call

Epsilon Energy Ltd. (NASDAQ: EPSN) will release its second quarter 2026 earnings on Wednesday, August 12, 2026, after market close. The company will also host a conference call to discuss its financial and operating results on Thursday, August 13, 2026, at 10:00 a.m. CT …

Silo Pharma Inc. Q4 2023 Earnings: Wider-Than-Expected Loss Weighs on Shares - Full Year Guidance

Epsilon Energy Ltd. Schedules Second Quarter 2026 Earnings Release and Conference Call

Epsilon Energy Ltd. announced it will release its second quarter 2026 earnings on Wednesday, August 12, 2026, after market close. The company will also host a conference call to discuss its financial and operating results on Thursday, August 13, 2026, at 10:00 a.m. Central …